PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. It focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia. PROCEPT BioRobotics Corporation is based in REDWOOD CITY, Calif.
Revenue (Most Recent Fiscal Year) | $224.50M |
Net Income (Most Recent Fiscal Year) | $-91.41M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 12.89 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.85 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -40.72% |
Net Margin (Trailing 12 Months) | -40.72% |
Return on Equity (Trailing 12 Months) | -31.54% |
Return on Assets (Trailing 12 Months) | -21.96% |
Current Ratio (Most Recent Fiscal Quarter) | 9.07 |
Quick Ratio (Most Recent Fiscal Quarter) | 8.01 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.13 |
Inventory Turnover (Trailing 12 Months) | 1.82 |
Book Value per Share (Most Recent Fiscal Quarter) | $7.71 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.35 |
Earnings per Share (Most Recent Fiscal Year) | $-1.75 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.76 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Medical Devices |
Common Shares Outstanding | 54.82M |
Free Float | 45.28M |
Market Capitalization | $2.89B |
Average Volume (Last 20 Days) | 1.01M |
Beta (Past 60 Months) | 1.09 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 17.40% |
Percentage Held By Institutions (Latest 13F Reports) | 89.46% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |